Patents by Inventor Magnus Pfahl

Magnus Pfahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7226940
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 5, 2007
    Assignees: Incyte San Diego, Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Patent number: 7196108
    Abstract: The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: March 27, 2007
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Richard M. Fine, Lyle W. Spruce, James W. Zapf
  • Patent number: 7153875
    Abstract: The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) ----- represents a bond present or absent; and (g) W, X, Y and Z are independently or together —C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: December 26, 2006
    Assignee: Incyte San Diego
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P.M. Pleynet, Lyle W. Spruce, Torsten R. Wiemann, Jason B. Ibarra
  • Publication number: 20060241138
    Abstract: The present invention relates to methods of treating breast cancer, diabetes, and/or related metabolic disorders with certain substituted heterocycles of Formula (200), wherein B, H, I, J and K together with the Ar5 form a ring containing at least one amide residue, and W, X, Y and Z together form a 2,4-thiazolidinedione, 2-thioxo-thiazolidine-4-one, 2,4-imidazolidinedione or 2-thioxo-imidazolidine-4-one residue; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2006
    Publication date: October 26, 2006
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien Al-Shamma, Andrea Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Mohamed Boudjelal, James Zapf
  • Patent number: 7102000
    Abstract: The present invention relates to certain substituted heterocycles of Formula (200), wherein B, H, I, J and K together with the Ar5 form a ring containing at least one amide residue, and W, X, Y and Z together form a 2,4-thiazolidinedione, 2-thioxo-thiazolidine-4-one, 2,4-imidazolidinedione or 2-thioxo-imidazolidine-4-one residue; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of diseases such as type 2 diabetes, and related disorders of lipid and carbohydrate metabolism, including atherosclerosis. The compounds are also useful for treating diseases of uncontrolled proliferation, such as cancers in general, including breast cancer.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: September 5, 2006
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Mohamed Boudjelal, James W. Zapf
  • Patent number: 7098310
    Abstract: This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.
    Type: Grant
    Filed: December 24, 1991
    Date of Patent: August 29, 2006
    Assignee: Ligand Pharmaceuticals
    Inventors: Magnus Pfahl, Xiao-kun Zhang
  • Publication number: 20060160796
    Abstract: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:
    Type: Application
    Filed: March 20, 2006
    Publication date: July 20, 2006
    Inventors: Magnus Pfahl, Catherine Tachdjian, Lyle Spruce, Hussien Al-Shamma, Mohamed Boudjelal, Andrea Fanjul, Torsten Wiemann, David Pleynet
  • Patent number: 7071218
    Abstract: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: July 4, 2006
    Assignees: Incyte San Diego Incorporated, Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Lyle W. Spruce, Hussien A. Al-Shamma, Mohamed Boudjelal, Andrea N. Fanjul, Torsten R. Wiemann, David P. M. Pleynet
  • Patent number: 7026125
    Abstract: This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: April 11, 2006
    Assignee: Ligand Pharmaceuticals
    Inventors: Magnus Pfahl, Xiao-kun Zhang
  • Publication number: 20060004059
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Application
    Filed: August 24, 2005
    Publication date: January 5, 2006
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussein Al-Shamma, Andrea Fanjul, David Pleynet, Lyle Spruce
  • Patent number: 6974826
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: December 13, 2005
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Publication number: 20050209286
    Abstract: Disclosed are molecules that activate an RXR receptor, wherein the molecule comprises an RXR binding portion which binds the RXR receptor and comprises a side pocket contacting residue which contacts a side-pocket 1 of an RXR receptor.
    Type: Application
    Filed: March 1, 2005
    Publication date: September 22, 2005
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien Al-Shamma, Andrea Fanjul, David Pleynet, Lyle Spruce, Richard Fine, James Zapf, Jianhua Guo, Karine Jakubowicz-Jaillardon
  • Publication number: 20050070581
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Application
    Filed: July 19, 2004
    Publication date: March 31, 2005
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien Al-Shamma, Andrea Fanjul, David Pleynet, Lyle Spruce
  • Publication number: 20050038098
    Abstract: The invention relates to novel heterocyclic compounds having the structure illustrated by Formula (I) wherein the Ar1 radicals are substituted dihydronapthalene or isochroman radicals, the Ar2 radicals are aryl or heteroaryl radicals; and HAr is a 2,4-thiazolidinedione, 2-thioxo-thiazolidine-4-one, 2,4-imidazolidinedione or 2-thioxo-imidazolidine-4-one radical. The compounds of Formula (I) can have biological activity for advantageously regulating carbohydrate metabolism, including serum glucose level, and lipid metabolism, and can be useful for the treatment of hyperlipidemia and/or hypercholesterolemia, and Type II diabetes. The compounds of Formula (I) can also have utility in the treatment of diseases of uncontrolled proliferation, including cancer.
    Type: Application
    Filed: April 19, 2004
    Publication date: February 17, 2005
    Inventors: Catherine Tachdjian, Jianhua Guo, Mohamed Boudjelal, Hussien Al-Shamma, Andrea Giachino, Karine Jakubowicz-Jaillardon, Qing Chen, James Zapf, Magnus Pfahl
  • Publication number: 20050014767
    Abstract: The invention relates to certain compounds whose structures are shown below, and their pharmaceutically acceptable salts and prodrugs, and pharmaceutical compositions thereof, which are useful for treating treating diseases of uncontrolled cellular proliferation, including cancer.
    Type: Application
    Filed: January 29, 2004
    Publication date: January 20, 2005
    Inventors: Magnus Pfahl, Catherine Tachdjian, Torsten Wiemann, Christopher Cow, Lyle Spruce, Andrea Giachino, Allan Kaspar, James Zapf
  • Patent number: 6825226
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoicacid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: November 30, 2004
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 6765013
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: July 20, 2004
    Assignee: Incyte San Diego
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Publication number: 20040097566
    Abstract: The present invention relates to certain substituted heterocycles, including 2-substituted thiazolidinone and 2-substituted oxazolidinone compounds. These compounds are useful in the treatment of diseases related to uncontrolled cellular proliferation, such as cancer or precancerous conditions. The compounds are also useful for modulating lipid and/or carbohydrate metabolism, and treating Type II diabetes, hyperglycemia or obesity, and for treating inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 6, 2002
    Publication date: May 20, 2004
    Inventors: Magnus Pfahl, Hussien A. Al-Shamma, Andrea Fanjul Giachino, David P. M. Pleynet, Haifeng Bao, Lyle W. Spruce, Christopher N. Cow, Catherine Tachdjian, James W. Zapf, Torsten R. Wiemann
  • Publication number: 20040034004
    Abstract: The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.
    Type: Application
    Filed: March 6, 2003
    Publication date: February 19, 2004
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Richard M. Fine, Lyle W. Spruce, James W. Zapf
  • Patent number: 6683047
    Abstract: This invention provides a method of inhibiting the transcription of a gene, which is activated by AP-1 or an AP-1 component, comprising binding AP-1 or the component with a nuclear receptor so as to prevent the binding of AP-1 to the gene. The nuclear receptor can be the retinoic acid receptor, glucocorticoid receptor, vitamin D3 receptor, thyroid receptor, or estrogen receptor. Also provided is a composition of matter comprising AP-1 or an AP-1 component bound to a nuclear receptor. These methods and compositions can be used to treat arthritis and cancer.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: January 27, 2004
    Assignees: The Burnham Institute, The Regents of the University of California
    Inventors: Magnus Pfahl, Michael Karin